Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study | Zendy

Ronan Flippot | Zendy; Cécile Dalban | Zendy; Brigitte Laguerre | Zendy; Delphine Borchiellini | Zendy; Gwénaëlle Gravis | Zendy; Sylvie Négrier | Zendy; Christine Chevreau | Zendy; Florence Joly | Zendy; Lionnel Geoffrois | Zendy; Sylvain Ladoire | Zendy; Hakim Mahammedi | Zendy; Frédéric Rolland | Zendy; Marine GrossGoupil | Zendy; Élise Deluche | Zendy; Frank Priou | Zendy; Mathieu Laramas | Zendy; Philippe Barthélémy | Zendy; Bérengère Narciso | Zendy; Nadine Houédé | Zendy; Stéphane Culine | Zendy; Stéphane Oudard | Zendy; Marina Chenot | Zendy; Florence Tantot | Zendy; Sylvie Chabaud | Zendy; Bernard Escudier | Zendy; Laurence Albigès | Zendy

Open Access

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Author(s) -

Ronan Flippot,

Cécile Dalban,

Brigitte Laguerre,

Delphine Borchiellini,

Gwénaëlle Gravis,

Sylvie Négrier,

Christine Chevreau,

Florence Joly,

Lionnel Geoffrois,

Sylvain Ladoire,

Hakim Mahammedi,

Frédéric Rolland,

Marine GrossGoupil,

Élise Deluche,

Frank Priou,

Mathieu Laramas,

Philippe Barthélémy,

Bérengère Narciso,

Nadine Houédé,

Stéphane Culine,

Stéphane Oudard,

Marina Chenot,

Florence Tantot,

Sylvie Chabaud,

Bernard Escudier,

Laurence Albigès

Publication year - 2019

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.18.02218

Subject(s) - medicine , cohort , renal cell carcinoma , hazard ratio , nivolumab , oncology , clinical endpoint , brain metastasis , population , surgery , cancer , metastasis , clinical trial , immunotherapy , confidence interval , environmental health

Nivolumab activity is limited in patients with untreated brain metastases from ccRCC. Brain imaging and focal therapy should be considered before immune checkpoint inhibitors in patients with metastatic ccRCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research